Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach?

A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach? Am J Cardiovasc Drugs (2015) 15:113–133 DOI 10.1007/s40256-014-0100-5 SYSTEMATIC REVIEW A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach? • • Carlos Brotons Robert Benamouzig • • Krzysztof J. Filipiak Volker Limmroth Claudio Borghi Published online: 12 December 2014 The Author(s) 2014. This article is published with open access at Springerlink.com Abstract establish CVD-based studies, cancer-based studies, and Background and Objectives While evidence in support of studies on adherence. aspirin use in secondary prevention is well documented, the Study Eligibility Criteria Date restrictions of May 31, role of aspirin in primary prevention remains unclear. We 2008 to May 31, 2013 were applied to capture the most conducted a systematic literature review to evaluate aspirin use robust meta-analyses and randomized controlled trials. in cardiovascular disease (CVD) and cancer primary preven- Websites of relevant EU and US scientific societies were tion, and consider whether aspirin’s role is set to become more used to identify the key guidelines for aspirin use in pri- clearly defined based on past and prospective studies. mary prevention of CVD, and ClinicalTrials.gov was used Data Sources Utilizing PubMed, the reviewers identified to establish future or ongoing trials. appropriate Medical Subject Headings http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach?

Download PDF
21 pages

Loading next page...
 
/lp/springer-journals/a-systematic-review-of-aspirin-in-primary-prevention-is-it-time-for-a-rSzACXbvIL

References (94)

Publisher
Springer Journals
Copyright
Copyright © 2014 by The Author(s)
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-014-0100-5
pmid
25502483
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2015) 15:113–133 DOI 10.1007/s40256-014-0100-5 SYSTEMATIC REVIEW A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach? • • Carlos Brotons Robert Benamouzig • • Krzysztof J. Filipiak Volker Limmroth Claudio Borghi Published online: 12 December 2014 The Author(s) 2014. This article is published with open access at Springerlink.com Abstract establish CVD-based studies, cancer-based studies, and Background and Objectives While evidence in support of studies on adherence. aspirin use in secondary prevention is well documented, the Study Eligibility Criteria Date restrictions of May 31, role of aspirin in primary prevention remains unclear. We 2008 to May 31, 2013 were applied to capture the most conducted a systematic literature review to evaluate aspirin use robust meta-analyses and randomized controlled trials. in cardiovascular disease (CVD) and cancer primary preven- Websites of relevant EU and US scientific societies were tion, and consider whether aspirin’s role is set to become more used to identify the key guidelines for aspirin use in pri- clearly defined based on past and prospective studies. mary prevention of CVD, and ClinicalTrials.gov was used Data Sources Utilizing PubMed, the reviewers identified to establish future or ongoing trials. appropriate Medical Subject Headings

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Dec 12, 2014

There are no references for this article.